医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

バイオテクノロジー

AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

バイオテクノロジーヘルスケアヘルス一般医療機器　 TimeLine: $1 Million Research AVITA Medical Announces Receipt Development Tax Credit

2018年09月26日

0

Evaluate Ltd: Worldwide medtech Sales Forecast to Reach $595 Billion by 2024, with a CAGR of 5.6%, Anchored by Familiar Players

Evaluate Ltd: Worldwide medtech Sales Forecast to Reach $595 Billion by 2024, with a CAGR of 5.6%, Anchored by Familiar Players

バイオテクノロジーヘルスケア製薬　 TimeLine: Anchored by Familiar Players Billion by 2024 Evaluate Ltd with a CAGR of 5.6%Worldwide Medtech Sales Forecast to Reach

2018年09月25日

0

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ALTA-1L Trial Showing a Reduction in Risk First-Line Advanced ALK Progression or Death of More Than 50 Takeda to Present Positive Data from ALUNBRIG

2018年09月25日

0

产权组织和IFPMA发布新的在线专利检索资源，帮助卫生机构采购药品

产权组织和IFPMA发布新的在线专利检索资源，帮助卫生机构采购药品

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器医療用品製薬　 TimeLine: 助卫生机构采和IFPMA发布新的

2018年09月25日

0

WIPOとIFPMAが医療関係者の適切な医薬品の調達に貢献する新しいオンライン特許情報データベースを開設

WIPOとIFPMAが医療関係者の適切な医薬品の調達に貢献する新しいオンライン特許情報データベースを開設

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器医療用品製薬　 TimeLine: IFPMA WIPO 医療関係者医薬品新しいオンライン特許情報

2018年09月25日

0

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Alexion Announces Successful Phase 3 PREVENT Study in Patients with Neuromyelitis Optica Spectrum

2018年09月24日

0

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Approval in Japan for Frontline Hodgkin Lymphoma Seattle Genetics Announces ADCETRIS

2018年09月21日

0

MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil

MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: for Contezolid and Contezolid Acefosamil MicuRx Announces Receipt of FDA's QIDP

2018年09月21日

0

SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

バイオテクノロジーヘルスケア幹細胞製薬　 TimeLine: Companies for Joint Research on the Appropriate Notice Regarding an Equity and Business Alliance Stable Distribution of Regenerative Cell Medicine

2018年09月21日

0

SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

バイオテクノロジーヘルスケア幹細胞臨床試験製薬　 TimeLine: and Business Alliance Between Five Companies for and Stable Distribution of Regenerative Cell Appropriate Use Medicine SB623 Supplementary Information to the Notice Regarding

2018年09月21日

0